
Deirdre A Lane

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5079025/publications.pdf Version: 2024-02-01



DEIDODE A LANE

#	Article	IF	CITATIONS
1	Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry. Clinical Research in Cardiology, 2022, 111, 70-84.	1.5	25
2	Mobile health solutions for atrial fibrillation detection and management: a systematic review. Clinical Research in Cardiology, 2022, 111, 479-491.	1.5	42
3	Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society, Europace, 2022, 24, 1844-1871.	0.7	11
4	Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention. International Journal of Clinical Practice, 2022, 2022, 1-8.	0.8	1
5	Warfarin—Is Self-Care the Best Care?. Thrombosis and Haemostasis, 2022, 122, 471-474.	1.8	2
6	Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry. European Journal of Internal Medicine, 2022, 99, 45-56.	1.0	5
7	Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESCâ€EHRA EURObservational research programme in atrial fibrillation general longâ€term registry. European Journal of Clinical Investigation, 2022, 52, e13773.	1.7	6
8	Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke. Stroke, 2022, 53, 1759-1763.	1.0	36
9	Managing Uncertainty: Physicians' Decision Making for Stroke Prevention for Patients with Atrial Fibrillation and Intracerebral Hemorrhage. Thrombosis and Haemostasis, 2022, 122, 1603-1611.	1.8	10
10	Supermarket/Hypermarket Opportunistic Screening for Atrial Fibrillation (SHOPS-AF): A Mixed Methods Feasibility Study Protocol. Journal of Personalized Medicine, 2022, 12, 578.	1.1	3
11	Exercise-Based Cardiac Rehabilitation Associates with Lower Major Adverse Cardiovascular Events in People with Stroke. Cerebrovascular Diseases, 2022, 51, 488-492.	0.8	4
12	Worldwide trends in antithrombotic therapy prescribing for atrial fibrillation: observations on the â€~transition era' to non-vitamin K antagonist oral anticoagulants. Europace, 2022, 24, 871-873.	0.7	2
13	Risk of Cerebrovascular Events in Intracerebral Hemorrhage Survivors With Atrial Fibrillation: A Nationwide Cohort Study. Stroke, 2022, 53, 2559-2568.	1.0	5
14	Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke. European Heart Journal, 2022, 43, 2442-2460.	1.0	43
15	Interactive Remote Patient Monitoring Devices for Managing Chronic Health Conditions: Systematic Review and Meta-analysis. Journal of Medical Internet Research, 2022, 24, e35508.	2.1	11
16	Oral anticoagulants and outcomes in adults ≥80 years with atrial fibrillation: A global federated health network analysis. Journal of the American Geriatrics Society, 2022, 70, 2386-2392.	1.3	10
17	Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 3788.	1.0	5
18	Effectiveness and Safety of Antithrombotic Medication in Patients With Atrial Fibrillation and Intracranial Hemorrhage: Systematic Review and Meta-Analysis. Stroke, 2022, 53, 3035-3046.	1.0	3

#	Article	lF	CITATIONS
19	Epidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: A systematic review and meta-regression. European Journal of Internal Medicine, 2022, 103, 84-94.	1.0	13
20	The importance of adherence and persistence with oral anticoagulation treatment in patients with atrial fibrillation. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f81-f83.	1.4	8
21	Optimization of atrial fibrillation care: management strategies and quality measures. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 121-133.	1.8	3
22	Atrial fibrillation and the risk of 30â€day incident thromboembolic events, and mortality in adultsÂ≥Â50 years with COVIDâ€19. Journal of Arrhythmia, 2021, 37, 231-237.	0.5	30
23	End-Stage renal disease and 30-day mortality for adults with and without COVID-19. European Journal of Internal Medicine, 2021, 83, 93-95.	1.0	1
24	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	1.0	5,583
25	Quality indicators for the care and outcomes of adults with atrial fibrillation. Europace, 2021, 23, 494-495.	0.7	64
26	Higher Mortality of Ischaemic Stroke Patients Hospitalized with COVID-19 Compared to Historical Controls. Cerebrovascular Diseases, 2021, 50, 326-331.	0.8	25
27	2021 ISHNE/HRS/EHRA/APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals. Journal of Arrhythmia, 2021, 37, 271-319.	0.5	21
28	2021 ISHNE/ HRS/ EHRA/ APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals. Annals of Noninvasive Electrocardiology, 2021, 26, e12795.	0.5	29
29	Antithrombotic therapy for stroke prevention in patients with atrial fibrillation who survive an intracerebral haemorrhage: results of an EHRA survey. Europace, 2021, 23, 806-814.	0.7	4
30	2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009204.	2.1	45
31	2021 ISHNE/HRS/EHRA/APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals. Cardiovascular Digital Health Journal, 2021, 2, 4-54.	0.5	10
32	Beyond the 2020 guidelines on atrial fibrillation of the European society of cardiology. European Journal of Internal Medicine, 2021, 86, 1-11.	1.0	40
33	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace, 2021, 23, 1612-1676.	0.7	494
34	Mobile Apps to Improve Medication Adherence in Cardiovascular Disease: Systematic Review and Meta-analysis. Journal of Medical Internet Research, 2021, 23, e24190.	2.1	64
35	Associations between COVID-19 and 30-day thromboembolic events and mortality in people with dementia receiving antipsychotic medications. Pharmacological Research, 2021, 167, 105534.	3.1	13
36	The Atrial Fibrillation Better Care pathway for managing atrial fibrillation: a review. Europace, 2021, 23, 1511-1527.	0.7	21

#	Article	IF	CITATIONS
37	Exerciseâ€Based Cardiac Rehabilitation and Allâ€Cause Mortality Among Patients With Atrial Fibrillation. Journal of the American Heart Association, 2021, 10, e020804.	1.6	18
38	The Role of Acceptance and Commitment Therapy in Cardiovascular and Diabetes Healthcare: A Scoping Review. International Journal of Environmental Research and Public Health, 2021, 18, 8126.	1.2	9
39	Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVIDâ€19 patients. European Journal of Clinical Investigation, 2021, 51, e13679.	1.7	63
40	Association of Exercise-Based Cardiac Rehabilitation with Progression of Paroxysmal to Sustained Atrial Fibrillation. Journal of Clinical Medicine, 2021, 10, 435.	1.0	4
41	2021 ISHNE / HRS / EHRA / APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals. European Heart Journal Digital Health, 2021, 2, 7-48.	0.7	4
42	Patient Satisfaction: A Key Component in Increasing Treatment Adherence and Persistence. Thrombosis and Haemostasis, 2021, 121, 255-257.	1.8	3
43	Prevalence of atrial fibrillation and outcomes in older long-term care residents: a systematic review. Age and Ageing, 2021, 50, 744-757.	0.7	8
44	Utilization and perception of same-day discharge in electrophysiological procedures and device implantations: an EHRA survey. Europace, 2021, 23, 149-156.	0.7	14
45	Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. BMC Medicine, 2021, 19, 256.	2.3	22
46	Prospective randomised trial examining the impact of an educational intervention versus usual care on anticoagulation therapy control based on an SAMe-TT ₂ R ₂ score-guided strategy in anticoagulant-naÃ-ve Thai patients with atrial fibrillation (TREATS-AF): a study protocol. BMJ Open, 2021, 11, e051987.	0.8	4
47	Impact of mental health conditions on anticoagulation prescription in people with atrial fibrillation. European Heart Journal Quality of Care & Clinical Outcomes, 2021, , .	1.8	0
48	Modelling of longitudinal data to predict cardiovascular disease risk: a methodological review. BMC Medical Research Methodology, 2021, 21, 283.	1.4	5
49	444 Epidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: a systematic review and meta-regression. European Heart Journal Supplements, 2021, 23, .	0.0	0
50	The Effects of Implementing a Mobile Health–Technology Supported Pathway on Atrial Fibrillation–Related Adverse Events Among Patients With Multimorbidity. JAMA Network Open, 2021, 4, e2140071.	2.8	27
51	Educational Impact on Apixaban Adherence in Atrial Fibrillation (the AEGEAN STUDY): A Randomized Clinical Trial. American Journal of Cardiovascular Drugs, 2020, 20, 61-71.	1.0	22
52	Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program. Thrombosis and Haemostasis, 2020, 120, 027-035.	1.8	35
53	Validation of the modified Microlife blood pressure monitor in patients with paroxysmal atrial fibrillation. Clinical Research in Cardiology, 2020, 109, 802-809.	1.5	6
54	â€ [~] Real-world' observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). Europace, 2020, 22, 831-832.	0.7	18

Deirdre A Lane

#	Article	IF	CITATIONS
55	Reducing risk of adverse cardiovascular and renal outcomes for patients with atrial fibrillation and type 2 diabetes. European Journal of Heart Failure, 2020, 22, 136-138.	2.9	3
56	Lipid levels, atrial fibrillation and the impact of age: Results from the LIPIDOGRAM2015 study. Atherosclerosis, 2020, 312, 16-22.	0.4	25
57	Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials. European Heart Journal Supplements, 2020, 22, 11-112.	0.0	4
58	Homelessness: a â€~cause of the causes' of cardiovascular disease?. Heart, 2020, 106, 1456-1457.	1.2	2
59	Mobile health applications for managing atrial fibrillation for healthcare professionals and patients: a systematic review. Europace, 2020, 22, 1567-1578.	0.7	23
60	Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. PLoS Medicine, 2020, 17, e1003321.	3.9	331
61	Mobile health technology facilitates population screening and integrated care management in patients with atrial fibrillation. European Heart Journal, 2020, 41, 1617-1619.	1.0	10
62	Clinicians' views and experiences of prescribing oral anticoagulants for stroke prevention in atrial fibrillation: A qualitative meta-synthesis. PLoS ONE, 2020, 15, e0232484.	1.1	13
63	Letter by Guo et al Regarding Article, "SUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation― Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006635.	0.9	0
64	Comprehensive Management With the ABC (Atrial Fibrillation Better Care) Pathway in Clinically Complex Patients With Atrial Fibrillation: A Post Hoc Ancillary Analysis From the AFFIRM Trial. Journal of the American Heart Association, 2020, 9, e014932.	1.6	84
65	Anticoagulation control in different ethnic groups receiving vitamin K antagonist therapy for stroke prevention in atrial fibrillation. Thrombosis Research, 2020, 192, 12-20.	0.8	12
66	The Euro Heart Survey and EURObservational Research Programme (EORP) in atrial fibrillation registries: contribution to epidemiology, clinical management and therapy of atrial fibrillation patients over the last 20Âyears. Internal and Emergency Medicine, 2020, 15, 1183-1192.	1.0	25
67	The potential for photoplethysmographic (PPG)-based smart devices in atrial fibrillation detection. Expert Review of Medical Devices, 2020, 17, 253-255.	1.4	2
68	The Compelling Issue of Nonvitamin K Antagonist Oral Anticoagulant Adherence in Atrial Fibrillation Patients: A Systematic Need for New Strategies. Thrombosis and Haemostasis, 2020, 120, 369-371.	1.8	11
69	Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies. Frontiers in Medicine, 2020, 7, 54.	1.2	18
70	Peri-procedural management, implantation feasibility, and short-term outcomes in patients undergoing implantation of leadless pacemakers: European Snapshot Survey. Europace, 2020, 22, 833-838.	0.7	11
71	Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2020, 75, 1523-1534.	1.2	209
72	Lifestyle and risk factor modification for reduction of atrial fibrillation: We could do more. Trends in Cardiovascular Medicine, 2020, 30, 387-388.	2.3	1

#	Article	IF	CITATIONS
73	Considerations when choosing an appropriate bleeding risk assessment tool for patients with atrial fibrillation. Journal of Thrombosis and Haemostasis, 2020, 18, 788-790.	1.9	5
74	Etiologic Workup in Cases of Cryptogenic Stroke. Stroke, 2020, 51, 1419-1427.	1.0	29
75	Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial. American Journal of Medicine, 2020, 133, 1195-1202.e2.	0.6	80
76	Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. European Heart Journal, 2020, 41, 1132-1140.	1.0	50
77	Stroke and bleeding risk stratification in atrial fibrillation: a critical appraisal. European Heart Journal Supplements, 2020, 22, O14-O27.	0.0	17
78	Atrial fibrillation in low- and middle-income countries: a narrative review. European Heart Journal Supplements, 2020, 22, O61-O77.	0.0	22
79	Integrated care for the management of atrial fibrillation: what are the key components and important outcomes?. Europace, 2019, 21, 1759-1761.	0.7	5
80	Guideline-Adherent Treatment for Stroke and Death in Atrial Fibrillation Patients From UK and Japanese AF Registries. Circulation Journal, 2019, 83, 2434-2442.	0.7	6
81	Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation. Journal of the American College of Cardiology, 2019, 74, 2365-2375.	1.2	294
82	Warfarin Therapy and Improved Anticoagulation Control by Patient Self-Management. Thrombosis and Haemostasis, 2019, 119, 1550-1552.	1.8	2
83	Improving the Prescription of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review. Thrombosis and Haemostasis, 2019, 119, 294-307.	1.8	46
84	Atrial Fibrillation and Cognitive Function. Journal of the American College of Cardiology, 2019, 73, 612-619.	1.2	133
85	Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: The mAFA (mAFâ€App) II randomised trial. International Journal of Clinical Practice, 2019, 73, e13352.	0.8	56
86	Anticoagulation for Atrial Fibrillation in Older Adults—Using Big Data for Big Questions. Thrombosis and Haemostasis, 2019, 119, 855-857.	1.8	4
87	The Liverpool Centre for Cardiovascular Science. European Heart Journal, 2019, 40, 957-958.	1.0	0
88	Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. Europace, 2019, 21, 1116-1125.	0.7	10
89	Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines. Canadian Journal of Cardiology, 2019, 35, 619-633.	0.8	48
90	Psychotropic drug use following venous thromboembolism versus diabetes mellitus in adolescence or young adulthood: a Danish nationwide cohort study. BMJ Open, 2019, 9, e026159.	0.8	2

#	Article	IF	CITATIONS
91	Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). Europace, 2019, 21, 844-845.	0.7	68
92	Etiologic workup in cases of cryptogenic stroke: protocol for a systematic review and comparison of international clinical practice guidelines. Systematic Reviews, 2019, 8, 331.	2.5	2
93	Cognitive Behavioral Therapy for Depression, Anxiety, and Stress in Caregivers of Dementia Patients: A Systematic Review and Meta-Analysis. Gerontologist, The, 2019, 59, e343-e362.	2.3	43
94	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de EstimulaciÃ ³ n Cardiaca y Electrofisiologia (SOLAECE). European Heart Journal, 2018, 39, ehw455.	1.0	28
95	Epidemiology of atrial fibrillation. International Journal of Clinical Practice, 2018, 72, e13070.	0.8	154
96	Use of leadless pacemakers in Europe: results of the European Heart Rhythm Association survey. Europace, 2018, 20, 555-559.	0.7	41
97	Incident Heart Failure in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study. Journal of the American Heart Association, 2018, 7, .	1.6	40
98	Individual depressive symptoms and all-cause mortality In 6673 patients with myocardial infarction: Heterogeneity across age and sex subgroups. Journal of Affective Disorders, 2018, 228, 178-185.	2.0	10
99	Innovative strategies to improve adherence to non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. European Heart Journal, 2018, 39, 1404-1406.	1.0	10
100	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. Europace, 2018, 20, 395-407.	0.7	95
101	Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: Results of a conjoint analysis. Clinical Cardiology, 2018, 41, 855-861.	0.7	31
102	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. Heart Rhythm, 2018, 15, e37-e60.	0.3	21
103	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. Europace, 2018, 20, 1399-1421.	0.7	75
104	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace, 2018, 20, 1231-1242.	0.7	194
105	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal, 2018, 39, 1330-1393.	1.0	1,576
106	Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE‣Y trial. Journal of Internal Medicine, 2018, 283, 282-292.	2.7	25
107	Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists: A review. Heart Rhythm, 2018, 15, 615-623.	0.3	23
108	Qualitative exploration of the effect of a television soap opera storyline on women with experience of postpartum psychosis. BJPsych Open, 2018, 4, 75-82.	0.3	5

#	Article	IF	CITATIONS
109	Patients' Perceptions of Atrial Fibrillation, Stroke Risk, and Oral Anticoagulation Treatment: An International Survey. TH Open, 2018, 02, e233-e241.	0.7	17
110	Effectiveness of Cognitive Behavioral Therapy for Depression and Anxiety in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. Psychosomatic Medicine, 2018, 80, 742-753.	1.3	123
111	Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. European Journal of Internal Medicine, 2018, 55, 28-34.	1.0	51
112	Use of NOACs in the Peri-Operative Management of Patients with Atrial Fibrillation: To Stop, Bridge or Continue?. Thrombosis and Haemostasis, 2018, 118, 1123-1126.	1.8	2
113	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?. Journal of Arrhythmia, 2018, 34, 99-123.	0.5	41
114	Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. American Journal of Medicine, 2018, 131, 1359-1366.e6.	0.6	129
115	Antithrombotic Therapy for Atrial Fibrillation. Chest, 2018, 154, 1121-1201.	0.4	718
116	Guideline-adherent secondary prevention post-acute coronary syndromes: the importance of patient uptake and persistence. European Heart Journal, 2018, 39, 2365-2367.	1.0	8
117	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Europace, 2017, 19, euw242.	0.7	67
118	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. Europace, 2017, 19, euw243.	0.7	86
119	Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. Europace, 2017, 19, euw150.	0.7	32
120	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. European Heart Journal, 2017, 38, ehw069.	1.0	106
121	Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care. Journal of the American Heart Association, 2017, 6, .	1.6	187
122	Clinical Features and Prognosis in Patients with Atrial Fibrillation and Prior Stroke: Comparing the Fushimi and Darlington AF Registries. EBioMedicine, 2017, 18, 199-203.	2.7	18
123	Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. The Cochrane Library, 2017, 2017, CD008600.	1.5	66
124	Patients' experiences of atrial fibrillation and non-vitamin K antagonist oral anticoagulants (NOACs), and their educational needs: A qualitative study. Thrombosis Research, 2017, 153, 19-27.	0.8	35
125	Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial. American Journal of Medicine, 2017, 130, 1388-1396.e6.	0.6	172
126	Bleeding Risk Scores in Atrial Fibrillation and Venous Thromboembolism. American Journal of Cardiology, 2017, 120, 1139-1145.	0.7	44

#	Article	IF	CITATIONS
127	Effects of cognitive behavioural therapy for depression in heart failure patients: a systematic review and meta-analysis. Heart Failure Reviews, 2017, 22, 731-741.	1.7	98
128	Guideline-Adherent Antithrombotic Treatment Improves Outcomes in Patients With Atrial Fibrillation. Mayo Clinic Proceedings, 2017, 92, 1203-1213.	1.4	34
129	Secondary Versus Primary Stroke Prevention in Atrial Fibrillation: Insights From the Darlington Atrial Fibrillation Registry. Stroke, 2017, 48, 2198-2205.	1.0	29
130	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). European Journal of Preventive Cardiology, 2017, 24, 4-40.	0.8	83
131	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de EstimulaciÃ ³ n Cardiaca y Electrofisiologia (SOLAECE). Europace, 2017, 19, 465-511.	0.7	118
132	Device-detected subclinical atrial tachyarrhythmias: definition, implications and management—an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de EstimulaciÃ ³ n CardÃaca y ElectrofisiologÃa (SOLEACE). Europace, 2017, 19, 1556-1578.	0.7	186
133	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de EstimulaciÃ3n CardÃaca y ElectrofisiologÃa (SOLAECE), Europace, 2017, 19, 1589-1623. Antithrombotic therapy in atrial fibrillation associated with Valvuar heart disease: a joint consensus	0.7	208
134	document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de	0.7	107
135	Estimulación CardÃaca y. Europace, 2017, 19, 1757-1758. Streamlining primary and secondary care management pathways for stroke prevention in atrial fibrillation. European Heart Journal, 2017, 38, 2980-2982.	1.0	10
136	Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Thrombosis and Haemostasis, 2017, 117, 209-218.	1.8	161
137	Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association	1.8	41
138	and Sociedad Latinoamericana de Es. Thrombosis and Haemostasis, 2017, 117, 2215-2236. Executive Summary: European Heart Rhythm Association Consensus Document on the Management of Supraventricular Arrhythmias. Arrhythmia and Electrophysiology Review, 2016, 5, 210.	1.3	4
139	Developing a Complex Educational–Behavioural Intervention: The TREAT Intervention for Patients with Atrial Fibrillation. Healthcare (Switzerland), 2016, 4, 10.	1.0	6
140	Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. Journal of Thrombosis and Haemostasis, 2016, 14, 1711-1714.	1.9	97
141	Stroke and death in elderly patients with atrial fibrillation in Japan compared with the United Kingdom. Heart, 2016, 102, 1878-1882.	1.2	18
142	Adolescents' and Young Adults' Lived Experiences Following Venous Thromboembolism. Nursing Research, 2016, 65, 455-464.	0.8	19
143	Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. Scientific Reports, 2016, 6, 24376.	1.6	49
144	Relation of the SAMe-TT 2 R 2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials. International Journal of Cardiology, 2016, 216, 168-172.	0.8	21

#	Article	IF	CITATIONS
145	Stroke prevention in atrial fibrillation: can we do better?. Nature Reviews Cardiology, 2016, 13, 511-512.	6.1	3
146	Thromboprophylaxis in atrial fibrillation and association with cognitive decline: systematic review. Age and Ageing, 2016, 45, 767-775.	0.7	64
147	International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives. Journal of the American Heart Association, 2016, 5, .	1.6	18
148	Atrial fibrillation. Nature Reviews Disease Primers, 2016, 2, 16016.	18.1	185
149	The 5-factor ORBIT bleeding score predicted major bleeding at 2 years in patients with atrial fibrillation. Annals of Internal Medicine, 2016, 164, JC11.	2.0	2
150	Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials. EBioMedicine, 2016, 8, 309-316.	2.7	31
151	Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials). American Journal of Cardiology, 2016, 118, 72-78.	0.7	25
152	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. European Heart Journal, 2016, 38, ehv643.	1.0	69
153	Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes. International Journal of Cardiology, 2016, 203, 660-666.	0.8	161
154	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace, 2016, 18, 37-50.	0.7	121
155	Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. American Journal of Medicine, 2016, 129, 600-607.	0.6	101
156	Patients' and physicians' experiences of atrial fibrillation consultations and anticoagulation decision-making: A multi-perspective IPA design. Psychology and Health, 2016, 31, 436-455.	1.2	43
157	European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace, 2016, 18, 12-36.	0.7	66
158	A bifactor model of the Beck Depression Inventory and its association with medical prognosis after myocardial infarction Health Psychology, 2016, 35, 614-624.	1.3	16
159	Patient-Reported Outcomes for Quality of Life Assessment in Atrial Fibrillation: A Systematic Review of Measurement Properties. PLoS ONE, 2016, 11, e0165790.	1.1	44
160	Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease. Current Medicinal Chemistry, 2016, 23, 2055-2069.	1.2	3
161	Net clinical benefit of edoxaban versus no treatment in a â€ [~] real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study. International Journal of Cardiology, 2015, 201, 693-698.	0.8	18
162	Optimising stroke prevention in patients with atrial fibrillation. British Journal of General Practice, 2015, 65, 117-117.	0.7	3

#	Article	IF	CITATIONS
163	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in Japanese Patients With Atrial Fibrillation. Circulation Journal, 2015, 79, 339-345.	0.7	35
164	Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. British Journal of General Practice, 2015, 65, e16-e23.	0.7	37
165	Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic. International Journal of Clinical Practice, 2015, 69, 1341-1348.	0.8	17
166	Nonâ€vitamin K antagonist oral anticoagulants (<scp>NOACs</scp>) in patients with concomitant atrial fibrillation and heart failure: a systemic review and metaâ€analysis of randomized trials. European Journal of Heart Failure, 2015, 17, 1192-1200.	2.9	113
167	Stroke Prevention in Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2015, 313, 1950.	3.8	258
168	Gender differences in stroke prevention in atrial fibrillation in general practice: using the GRASP-AF audit tool. International Journal of Clinical Practice, 2015, 69, 840-845.	0.8	25
169	Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de EstimulaciÃ ³ n CardÃaca y ElectrofisiologÃa (SOLEACE), Europace, 2015, 17, 1747-1769.	0.7	119
170	Difficult decision making in the management of patients with atrial fibrillation and acute coronary syndrome or invasive cardiovascular interventions: new recommendations for daily practice. Europace, 2015, 17, 1319-1322.	0.7	5
171	Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. Journal of Thrombosis and Haemostasis, 2015, 13, 495-504.	1.9	129
172	Patient Guide for Taking the Non–Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation. Circulation, 2015, 131, e412-5.	1.6	13
173	Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation. Stroke, 2015, 46, 2523-2528.	1.0	57
174	Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. Age and Ageing, 2015, 44, 874-878.	0.7	57
175	Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace, 2015, 17, 1169-1196.	0.7	138
176	Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation. Stroke, 2015, 46, 2168-2174.	1.0	72
177	Use of psychotropic drugs following venous thromboembolism in youth. A nationwide cohort study. Thrombosis Research, 2015, 135, 643-647.	0.8	15
178	Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes. Europace, 2015, 17, 507-508.	0.7	20
179	Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clinical Research in Cardiology, 2015, 104, 418-429.	1.5	87
180	Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy, 2015, 13, 1155-1163.	0.6	1

#	Article	IF	CITATIONS
181	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace, 2015, 17, euv319.	0.7	635
182	Assessment of the CHA ₂ DS ₂ -VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2015, 314, 1030.	3.8	262
183	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2015, 17, 1467-1507.	0.7	951
184	Sex differences in clinical characteristics and inpatient outcomes among 2442 hospitalized Chinese patients with nonvalvular atrial fibrillation: The Nanchang Atrial Fibrillation Project. International Journal of Cardiology, 2015, 201, 195-199.	0.8	7
185	Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ, The, 2015, 351, h4451.	3.0	247
186	Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus on the reversible bleeding risk factors. European Heart Journal, 2015, 36, ehv415.	1.0	36
187	Assessing Eligibility for Anticoagulation After Diagnosis of Atrial Fibrillation—Reply. JAMA - Journal of the American Medical Association, 2015, 314, 949.	3.8	1
188	Matching the NOAC to the Patient. Journal of the American College of Cardiology, 2015, 66, 2282-2284.	1.2	31
189	Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF population: A modeling analysis. International Journal of Cardiology, 2015, 181, 247-254.	0.8	7
190	Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. EuroIntervention, 2015, 10, 1015-1021.	1.4	21
191	Atrial fibrillation (chronic). Clinical Evidence, 2015, 2015, .	0.2	2
192	Stroke and Bleeding Risk in Atrial Fibrillation. Korean Circulation Journal, 2014, 44, 281.	0.7	32
193	Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. Thrombosis and Haemostasis, 2014, 112, 381-383.	1.8	64
194	Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation. Thrombosis and Haemostasis, 2014, 112, 789-795.	1.8	16
195	Diving to the foot of an iceberg: The SEARCH for undiagnosed atrial fibrillation. Thrombosis and Haemostasis, 2014, 112, 1-3.	1.8	101
196	Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 955-967.	0.2	124
197	Atrial Fibrillation in Cryptogenic Stroke. Stroke, 2014, 45, 3184-3185.	1.0	9
198	Use of the HAS-BLED bleeding score in real-life settings. Thrombosis Research, 2014, 134, 202.	0.8	2

#	Article	IF	CITATIONS
199	An evaluation of the Minnesota Living with Heart Failure Questionnaire using Rasch analysis. Quality of Life Research, 2014, 23, 1753-1765.	1.5	28
200	Myocardial Ischemic Events in â€~Real World' Patients with Atrial Fibrillation Treated with Dabigatran or Warfarin. American Journal of Medicine, 2014, 127, 329-336.e4.	0.6	63
201	The Reply. American Journal of Medicine, 2014, 127, e21.	0.6	0
202	Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation. Current Problems in Cardiology, 2014, 39, 319-344.	1.1	5
203	The Impact of Heart Failure and Left Ventricular Dysfunction in Predicting Stroke, Thromboembolism, and Mortality in Atrial Fibrillation Patients: A Systematic Review. Clinical Therapeutics, 2014, 36, 1135-1144.	1.1	57
204	Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study. American Journal of Medicine, 2014, 127, 1172-1178.e5. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary.	0.6	43
205	syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society	1.0	490
206	(HRS) and Asia-Pacific Heart Rhythm So. European Heart Journal, 2014, 35, 3155-3179. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace, 2014, 16, 1655-1673.	0.7	105
207	Atrial Fibrillation and Heart Failure: A Bad Combination. American Journal of Cardiology, 2014, 113, 1196-1197.	0.7	9
208	Modern Management of Atrial Fibrillation Requires Initial Identification of "Low-Risk―Patients Using the CHA ₂ DS ₂ -VASc Score, and Not Focusing on "High-Risk― Prediction. Circulation Journal, 2014, 78, 1843-1845.	0.7	26
209	Stroke and Bleeding Risk in Atrial Fibrillation: Navigating the Alphabet Soup of Risk‣core Acronyms (CHADS ₂ , CHA ₂ DS ₂ â€VASc, R ₂ CHADS ₂ ,) Tj ET(Qq1710.7	8 43 14 rgBT
210	The Impact of Smoking on Thromboembolism and Mortality in Patients With Incident Atrial Fibrillation. Chest, 2014, 145, 559-566.	0.4	54
211	The Value of the European Society of Cardiology Guidelines for Refining Stroke Risk Stratification in Patients With Atrial Fibrillation Categorized as Low Risk Using the Anticoagulation and Risk Factors in Atrial Fibrillation Stroke Score. Chest, 2014, 146, 1337-1346.	0.4	34
212	Best Practice for Atrial Fibrillation Patient Education. Current Pharmaceutical Design, 2014, 21, 533-543.	0.9	52
213	Matrix metalloproteinases and their tissue inhibitors in hypertension-related pregnancy complications. Journal of Human Hypertension, 2013, 27, 72-78.	1.0	30
214	Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study. Netherlands Heart Journal, 2013, 21, 354-363.	0.3	29
215	Bleeding risk during oral anticoagulation therapy for atrial fibrillation. Europace, 2013, 15, 773-774.	0.7	2
216	Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace, 2013, 15, 1540-1556.	0.7	125

#	Article	IF	CITATIONS
217	Pattern of atrial fibrillation and risk of outcomes: The Loire Valley Atrial Fibrillation Project. International Journal of Cardiology, 2013, 167, 2682-2687.	0.8	67
218	Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED Bleeding Risk–Prediction Scores in Nonwarfarin Anticoagulated Atrial Fibrillation Patients. Journal of the American College of Cardiology, 2013, 61, 386-387.	1.2	67
219	Reply. Journal of the American College of Cardiology, 2013, 61, 482-483.	1.2	0
220	Anticoagulation for AF: can we GRASP-AF patients?. Nature Reviews Cardiology, 2013, 10, 241-242.	6.1	1
221	Assessment of stroke risk in Middle Eastern patients with atrial fibrillation: The Gulf SAFE registry. International Journal of Cardiology, 2013, 168, 1644-1646.	0.8	14
222	Recent Developments in Understanding Epidemiology and Risk Determinants of Atrial Fibrillation as a Cause of Stroke. Canadian Journal of Cardiology, 2013, 29, S4-S13.	0.8	29
223	Treatment of hypertension in peripheral arterial disease. The Cochrane Library, 2013, , CD003075.	1.5	37
	Letter by Apostolakis et al Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R ₂ CHADS		

#	Article	IF	CITATIONS
235	Comparison of the CHADS2, CHA2DS2 -VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial. Thrombosis and Haemostasis, 2013, 110, 1074-1079.	1.8	98
236	Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. Thrombosis and Haemostasis, 2013, 109, 328-336.	1.8	56
237	Psychological interventions for depression in adolescent and adult congenital heart disease. The Cochrane Library, 2013, , CD004372.	1.5	27
238	Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. , 2013, , CD008600.		35
239	Development of a Novel Composite Stroke and Bleeding Risk Score in Patients With Atrial Fibrillation. Chest, 2013, 144, 1839-1847.	0.4	37
240	Educational Intervention Improves Anticoagulation Control in Atrial Fibrillation Patients: The TREAT Randomised Trial. PLoS ONE, 2013, 8, e74037.	1.1	165
241	Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review. Health Technology Assessment, 2013, 17, 1-188.	1.3	27
242	Assessing the Risk of Bleeding in Patients With Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 941-948.	2.1	68
243	Thromboâ€embolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. European Journal of Heart Failure, 2012, 14, 681-695.	2.9	71
244	Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. European Journal of Heart Failure, 2012, 14, 295-301.	2.9	96
245	Angiogenin and Hemoxygenase in Pregnancy. Angiology, 2012, 63, 194-198.	0.8	8
246	Soluble Fas and Fas Ligand in Pregnancy. Angiology, 2012, 63, 35-38.	0.8	9
247	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic optionsa report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace, 2012, 14, 8-27.	0.7	193
248	Risk Factors for Stroke and Thromboembolism in Relation to Age Among Patients With Atrial Fibrillation. Chest, 2012, 141, 147-153.	0.4	96
249	Lack of impact of pulse pressure on outcomes in patients with malignant phase hypertension. Journal of Hypertension, 2012, 30, 974-979.	0.3	11
250	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. Thrombosis and Haemostasis, 2012, 108, 1009-1022.	1.8	65
251	Stroke and Thromboembolism in Atrial Fibrillation. Circulation Journal, 2012, 76, 2289-2304.	0.7	131
252	Atrial fibrillation. Lancet, The, 2012, 379, 648-661.	6.3	337

#	Article	IF	CITATIONS
253	To the Editor— Adding renal dysfunction to CHA2DS2-VASc improves stroke prediction postcatheter ablation. Heart Rhythm, 2012, 9, e25.	0.3	0
254	C0320 Oral anticoagulation in atrial fibrillation, the patients and physicians experiences of the consultation: A qualitative study. Thrombosis Research, 2012, 130, S193.	0.8	0
255	C0386 A meta-synthesis of qualitative studies exploring patients' and healthcare professionals views of atrial fibrillation and oral anticoagulant therapy. Thrombosis Research, 2012, 130, S112-S113.	0.8	1
256	Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease. New England Journal of Medicine, 2012, 367, 625-635.	13.9	795
257	Patients' and health professionals' views and experiences of atrial fibrillation and oral-anticoagulant therapy: A qualitative meta-synthesis. Patient Education and Counseling, 2012, 88, 330-337.	1.0	53
258	The Global Burden of Atrial Fibrillation and Stroke. Chest, 2012, 142, 1489-1498.	0.4	335
259	The ATRIA Risk Scheme to Predict Warfarin-Associated Hemorrhage. Journal of the American College of Cardiology, 2012, 59, 194-195.	1.2	14
260	Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED Bleeding Risk–Prediction Scores in Patients With Atrial Fibrillation Undergoing Anticoagulation. Journal of the American College of Cardiology, 2012, 60, 861-867.	1.2	326
261	Vascular Disease and Stroke Risk in Atrial Fibrillation: A Nationwide Cohort Study. American Journal of Medicine, 2012, 125, 826.e13-826.e23.	0.6	73
262	Use of the CHA ₂ DS ₂ -VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation. Circulation, 2012, 126, 860-865.	1.6	327
263	RCPE UK Consensus Conference on †Approaching the comprehensive management. Journal of the Royal College of Physicians of Edinburgh, The, 2012, 42, 34-35.	0.2	24
264	Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a â€real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study. Thrombosis and Haemostasis, 2012, 107, 584-589.	1.8	289
265	Antithrombotic Therapy for Atrial Fibrillation. Chest, 2012, 141, e531S-e575S.	0.4	891
266	Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2011, 57, 173-180.	1.2	898
267	Severe Renal Impairment and Stroke Prevention in Atrial Fibrillation. Journal of the American College of Cardiology, 2011, 57, 1339-1348.	1.2	191
268	Comparative Analysis of the HAS-BLED Score With Other Bleeding Risk Scores, Using Estimates of Net Reclassification Improvement and Integrated Discrimination Improvement. Journal of the American College of Cardiology, 2011, 58, 1398-1399.	1.2	3
269	Bleeding Risk in Patients With Atrial Fibrillation. Chest, 2011, 140, 146-155.	0.4	26
270	Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a †real world' nationwide cohort study. Thrombosis and Haemostasis, 2011, 106, 739-749.	1.8	393

#	Article	IF	CITATIONS
271	Angiogenin and apoptosis in hypertension in pregnancy. Pregnancy Hypertension, 2011, 1, 191-196.	0.6	5
272	The Quest for New Anticoagulants: From Clinical Development to Clinical Practice. Cardiovascular Therapeutics, 2011, 29, e12-e22.	1.1	10
273	Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Thrombosis and Haemostasis, 2011, 106, 1012-1019	1.8	81
274	Bleeding risk assessment and management in atrial fibrillation patients. Thrombosis and Haemostasis, 2011, 106, 997-1011	1.8	234
275	Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnancies. Journal of Hypertension, 2011, 29, 396-399.	0.3	30
276	Assessing the Performance of the HAS-BLED Score: Response. Chest, 2011, 139, 1248.	0.4	0
277	Optimal Antithrombotic Therapy in Patients Receiving Long-term Oral Anticoagulation Requiring Percutaneous Coronary Intervention. Chest, 2011, 139, 240-243.	0.4	0
278	A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice. Journal of Thrombosis and Haemostasis, 2011, 9, 39-48.	1.9	240
279	Bleeding risk with oral anticoagulation - new frontiers and new questions. International Journal of Clinical Practice, 2011, 65, 719-721.	0.8	1
280	Stroke Risk Stratification in a "Real-World―Elderly Anticoagulated Atrial Fibrillation Population. Journal of Cardiovascular Electrophysiology, 2011, 22, 25-30.	0.8	63
281	Endothelial dysfunction in hypertension in pregnancy: associations between circulating endothelial cells, circulating progenitor cells and plasma von Willebrand factor. Clinical Research in Cardiology, 2011, 100, 531-537.	1.5	27
282	Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillation. Age and Ageing, 2011, 40, 653-655.	0.7	13
283	The HAS-BLED Score and Renal Failure: Response. Chest, 2011, 139, 1249-1250.	0.4	2
284	Can We IMPROVE Bleeding Risk Assessment for Acutely Ill, Hospitalized Medical Patients?. Chest, 2011, 139, 10-13.	0.4	19
285	Strategies to Improve Oral Anticoagulation Management. Chest, 2011, 140, 281-282.	0.4	1
286	An epidemic of atrial fibrillation?. Europace, 2011, 13, 1059-1060.	0.7	5
287	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace, 2011, 13, 723-746.	0.7	197
288	Short-Term Effects of Screening for Cardiovascular Risk in the Deaf Community: A Pilot Study. Cardiology Research and Practice, 2011, 2011, 1-5.	0.5	5

#	Article	IF	CITATIONS
289	Atrial fibrillation (chronic). Clinical Evidence, 2011, 2011, .	0.2	1
290	Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach. Chest, 2010, 137, 263-272.	0.4	5,657
291	Advances in therapy for atrial fibrillation. Therapy: Open Access in Clinical Medicine, 2010, 7, 103-105.	0.2	Ο
292	Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk. Lancet Neurology, The, 2010, 9, 1140-1142.	4.9	11
293	TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT). BMC Cardiovascular Disorders, 2010, 10, 21.	0.7	31
294	Anticoagulation for Atrial Fibrillation Patients with CHADS ₂ Score of 1. Journal of Cardiovascular Electrophysiology, 2010, 21, 508-510.	0.8	5
295	Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. Thrombosis and Haemostasis, 2010, 104, 122-127.	1.8	66
296	Anticoagulation intensity for elderly atrial fibrillation patients: Should we use a conventional INR target (2.0 to 3.0) or a lower range?. Thrombosis and Haemostasis, 2010, 103, 254-256.	1.8	6
297	Simplifying stroke risk stratification in atrial fibrillation patients: implications of the CHA2DS2-VASc risk stratification scores. Age and Ageing, 2010, 39, 533-535.	0.7	51
298	The assessment of stroke and bleeding risk in atrial fibrillation: where are we now?. Expert Review of Cardiovascular Therapy, 2010, 8, 1703-1710.	0.6	2
299	Atrial fibrillation and mortality: the impact of antithrombotic therapy. European Heart Journal, 2010, 31, 2075-2076.	1.0	5
300	Impact of symptom control on health-related quality of life in atrial fibrillation patients: the psychologist's viewpoint. Europace, 2010, 12, 608-610.	0.7	9
301	Obstructive Sleep Apnea Is a Risk Factor for Stroke and Atrial Fibrillation: Response. Chest, 2010, 138, 239-240.	0.4	4
302	CHA 2 DS 2 -VASc Risk Scheme: Response. Chest, 2010, 138, 1020-1021.	0.4	2
303	Identifying Patients at High Risk for Stroke Despite Anticoagulation. Stroke, 2010, 41, 2731-2738.	1.0	448
304	Stroke prevention in atrial fibrillation patients. Expert Opinion on Pharmacotherapy, 2010, 11, 2331-2350.	0.9	5
305	Age as a Risk Factor for Stroke in Atrial Fibrillation Patients. Journal of the American College of Cardiology, 2010, 56, 827-837.	1.2	206
306	Does Warfarin for Stroke Thromboprophylaxis Protect Against MI in Atrial Fibrillation Patients?. American Journal of Medicine, 2010, 123, 785-789.	0.6	100

#	Article	IF	CITATIONS
307	A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation. Chest, 2010, 138, 1093-1100.	0.4	3,810
308	Quality of anticoagulation control in atrial fibrillation. Lancet, The, 2010, 376, 935-937.	6.3	4
309	Haemorrhage risks, patient perspectives, and quality-of-life issues. , 2010, , 35-42.		0
310	Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillationâ€. Thrombosis and Haemostasis, 2009, 102, 914-915.	1.8	15
311	Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. Thrombosis and Haemostasis, 2009, 101, 802-805.	1.8	70
312	Impaired glucose tolerance and endothelial damage, as assessed by levels of von Willebrand factor and circulating endothelial cells, following acute myocardial infarction. Annals of Medicine, 2009, 41, 608-618.	1.5	6
313	Balancing Thromboembolism and Bleeding Risks. Chest, 2009, 136, 1451-1452.	0.4	1
314	Quality of life in older people with atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2009, 25, 37-42.	0.6	36
315	Improving Survival of Malignant Hypertension Patients Over 40 Years. American Journal of Hypertension, 2009, 22, 1199-1204.	1.0	95
316	Illness perceptions, affective response, and health-related quality of life in patients with atrial fibrillation. Journal of Psychosomatic Research, 2009, 66, 203-210.	1.2	89
317	Alcohol and Illicit Drug Use as Precipitants of Atrial Fibrillation in Young Adults: A Case Series and Literature Review. American Journal of Medicine, 2009, 122, 851-856.e3.	0.6	37
318	Treatment of hypertension in peripheral arterial disease. , 2009, , CD003075.		7
319	Bleeding rates in elderly patients on vitamin K antagonist therapy for nonvalvular atrial fibrillation. Blood Coagulation and Fibrinolysis, 2009, 20, 392-393.	0.5	6
320	Atrial fibrillation and stroke risk prevention in real-life clinical practice. Thrombosis and Haemostasis, 2009, 101, 415-416.	1.8	12
321	Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. Thrombosis and Haemostasis, 2009, 101, 802-5.	1.8	21
322	Vital exhaustion and cardiovascular disease: Are circulating fibrinogen and D-dimer levels a plausible link?. Stress, 2008, 11, 247-249.	0.8	4
323	Barriers to Anticoagulation in Patients With Atrial Fibrillation. Stroke, 2008, 39, 7-9.	1.0	45
324	Challenges facing anticoagulation among the elderly and frail. Age and Ageing, 2008, 38, 140-142.	0.7	6

#	Article	IF	CITATIONS
325	Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: Is clopidogrel any safer than aspirin when combined with warfarin?. Thrombosis and Haemostasis, 2008, 100, 955-957.	1.8	26
326	Amiloride 10 mg is less effective than spironolactone 25 mg in patients with hypertension resistant to a multidrug regime including an angiotensin-blocking agent. Journal of Hypertension, 2007, 25, 2515-2516.	0.3	18
327	Low-dose spironolactone in the management of resistant hypertension: a surveillance study. Journal of Hypertension, 2007, 25, 891-894.	0.3	116
328	Depression, Anxiety, and Quality of Life in Patients With Atrial Fibrillation. Chest, 2007, 132, 1259-1264.	0.4	232
329	Maintaining Therapeutic Anticoagulation. Chest, 2007, 131, 1277-1279.	0.4	21
330	Circulating Endothelial Cells, Arterial Stiffness, and Cardiovascular Risk Stratification in Hypertension. Chest, 2007, 132, 1540-1547.	0.4	26
331	A systematic review of the effects of acute psychological stress and physical activity on haemorheology, coagulation, fibrinolysis and platelet reactivity: Implications for the pathogenesis of acute coronary syndromes. Thrombosis Research, 2007, 120, 819-847.	0.8	115
332	Cross-cultural adaptation into Punjabi of the English version of the Hospital Anxiety and Depression Scale. BMC Psychiatry, 2007, 7, 5.	1.1	13
333	Quality of Life in Patients with Atrial Fibrillation: A Systematic Review. American Journal of Medicine, 2006, 119, 448.e1-448.e19.	0.6	502
334	Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: Effects of an educational intervention programme. International Journal of Cardiology, 2006, 110, 354-358.	0.8	152
335	Bleeding Risk Stratification Models in Deciding on Anticoagulation in Patients With Atrial Fibrillation. Chest, 2006, 130, 1296-1299.	0.4	18
336	Anticoagulation Control With Vitamin K Antagonists. Chest, 2006, 129, 1122-1124.	0.4	5
337	Additive Role of Plasma von Willebrand Factor Levels to Clinical Factors for Risk Stratification of Patients With Atrial Fibrillation. Stroke, 2006, 37, 2294-2300.	1.0	140
338	Temporal and venepuncture-related decline in circulating endothelial cell capture from mixed venous blood. Journal of Thrombosis and Thrombolysis, 2006, 22, 125-131.	1.0	14
339	Recruitment of ethnic minority patients to a cardiac rehabilitation trial: The Birmingham Rehabilitation Uptake Maximisation (BRUM) study [ISRCTN72884263]. BMC Medical Research Methodology, 2005, 5, 18.	1.4	32
340	Anti-thrombotic therapy for atrial fibrillation and patients' preferences for treatment. Age and Ageing, 2005, 34, 1-3.	0.7	18
341	Psychological interventions for depression in heart failure. The Cochrane Library, 2005, , CD003329.	1.5	38
342	Home-based versus hospital-based cardiac rehabilitation after myocardial infarction or revascularisation: design and rationale of the Birmingham Rehabilitation Uptake Maximisation Study (BRUM): a randomised controlled trial [ISRCTN72884263]. BMC Cardiovascular Disorders, 2003, 3, 10.	0.7	46

#	Article	IF	CITATIONS
343	In-hospital symptoms of depression do not predict mortality 3 years after myocardial infarction. International Journal of Epidemiology, 2002, 31, 1179-1182.	0.9	61
344	The prevalence and persistence of depression and anxiety following myocardial infarction. British Journal of Health Psychology, 2002, 7, 11-21.	1.9	159
345	Predictors of attendance at cardiac rehabilitation after myocardial infarction. Journal of Psychosomatic Research, 2001, 51, 497-501.	1.2	147
346	Mortality and Quality of Life 12 Months After Myocardial Infarction: Effects of Depression and Anxiety. Psychosomatic Medicine, 2001, 63, 221-230.	1.3	340
347	Do depression and anxiety predict recurrent coronary events 12 months after myocardial infarction?. QJM - Monthly Journal of the Association of Physicians, 2000, 93, 739-744.	0.2	52
348	Effects of depression and anxiety on mortality and quality-of-life 4 months after myocardial infarction. Journal of Psychosomatic Research, 2000, 49, 229-238.	1.2	137
349	Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10 220 patients from the European Society of Cardiology (ESC)-European Heart Rhythm Association (EHRA) EurObservational Research Programme on Atrial Fibrillation (EORP-AF) general long-term registry. European Journal of Preventive Cardiology, 0,	0.8	3